Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

JTO clinical and research reports

Showing results (1-10 of 735) with videos related to

Pageof 74
Sort By:
JTO Clinical and Research Reports|October 17, 2022
Successful Management of Generalized Myasthenia Gravis Induced by Atezolizumab in a Patient With Extensive-Stage SCLC: A Case ReportShuang Wu, Jiayu Shi, Yuzhou Guan, et al.
JTO Clinical and Research Reports|September 9, 2022
Role of 3'-Deoxy-3'-[<sup>18</sup>F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With PegargiminaseTeresa A Szyszko, Joel T Dunn, Melissa M Phillips, et al.
JTO Clinical and Research Reports|February 26, 2025
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50Yoshihito Kogure, Hiroya Hashimoto, Haruko Daga, et al.
JTO Clinical and Research Reports|January 31, 2025
Combined RET and MEK Inhibition as a Treatment for <i>RET</i> Fusion-Positive NSCLC With Acquired <i>BRAF</i> Fusion: A Case ReportJacobi B Hines, Benjamin C Bowar, Margaret Colleton, et al.
JTO Clinical and Research Reports|January 24, 2025
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLCFrancesca Lucibello, Valérie Gounant, Mihaela Aldea, et al.
JTO Clinical and Research Reports|January 13, 2025
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated TumorsAlissa J Cooper, Andrea Arfe, Biagio Ricciuti, et al.
JTO Clinical and Research Reports|January 6, 2025
Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?J Humberto Rodriguez-Quintero, Rajika Jindani, Roger Zhu, et al.
JTO Clinical and Research Reports|December 30, 2024
Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical ApplicationsMandy Jongbloed, Martina Bortolot, Leonard Wee, et al.
JTO Clinical and Research Reports|December 2, 2024
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18Dae-Ho Choi, Miso Kim, Young Saing Kim, et al.
JTO Clinical and Research Reports|November 25, 2024
Multisite Randomized Controlled Trial of CareSTEPS: A Supportive Care Intervention for the Family Caregivers of Patients With Advanced Lung CancerMaria L Rangel, Kathrin Milbury, Karen Kayser, et al.
Pageof 74

Showing results (1-10 of 735) with videos related to

Sort By:
Pageof 74
JTO Clinical and Research Reports|October 17, 2022
Successful Management of Generalized Myasthenia Gravis Induced by Atezolizumab in a Patient With Extensive-Stage SCLC: A Case ReportShuang Wu, Jiayu Shi, Yuzhou Guan, et al.
JTO Clinical and Research Reports|September 9, 2022
Role of 3'-Deoxy-3'-[<sup>18</sup>F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With PegargiminaseTeresa A Szyszko, Joel T Dunn, Melissa M Phillips, et al.
JTO Clinical and Research Reports|February 26, 2025
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50Yoshihito Kogure, Hiroya Hashimoto, Haruko Daga, et al.
JTO Clinical and Research Reports|January 31, 2025
Combined RET and MEK Inhibition as a Treatment for <i>RET</i> Fusion-Positive NSCLC With Acquired <i>BRAF</i> Fusion: A Case ReportJacobi B Hines, Benjamin C Bowar, Margaret Colleton, et al.
JTO Clinical and Research Reports|January 24, 2025
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLCFrancesca Lucibello, Valérie Gounant, Mihaela Aldea, et al.
JTO Clinical and Research Reports|January 13, 2025
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated TumorsAlissa J Cooper, Andrea Arfe, Biagio Ricciuti, et al.
JTO Clinical and Research Reports|January 6, 2025
Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?J Humberto Rodriguez-Quintero, Rajika Jindani, Roger Zhu, et al.
JTO Clinical and Research Reports|December 30, 2024
Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical ApplicationsMandy Jongbloed, Martina Bortolot, Leonard Wee, et al.
JTO Clinical and Research Reports|December 2, 2024
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18Dae-Ho Choi, Miso Kim, Young Saing Kim, et al.
JTO Clinical and Research Reports|November 25, 2024
Multisite Randomized Controlled Trial of CareSTEPS: A Supportive Care Intervention for the Family Caregivers of Patients With Advanced Lung CancerMaria L Rangel, Kathrin Milbury, Karen Kayser, et al.
Pageof 74